Close
Novotech
Jabsco PureFlo 21 Single Use

Clinical Trials

Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug product announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent...

Positive Dupilumab Topline Results From Phase 3 Trial In Uncontrolled Persistent Asthma Announced By Regeneron And Sanofi

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints. Dupilumab, when added to...

Presented in VIVA Late Breaking Clinical Trials Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data

Medtronic plc data announced reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The two-year, real-world results from the full clinical cohort of the IN.PACT Global...

License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia Completed By RegeneRX

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that it has completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical...

Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing

Blake Insomnia Therapeutics Inc. , a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application for Phase II clinical testing to Health...

Titan pharmaceuticals receives fda clearance to begin clinical study of parkinson’s disease treatment

Titan Pharmaceuticals, Inc. announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease. The Phase 1/2 clinical study...

Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis

Symic Bio, a biopharmaceutical company developing novel matrix regulators,announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »